Myelodysplastic syndromes (MDS) are a group of clonal myeloid neoplasms characterized by reduced and/or defective production of red blood cells, platelets, and mature granulocytes, often resulting in anemia, bleeding, increased risk of infection, and risk of transformation to AML. For many years, supportive therapy, blood transfusion, erythropoiesis-stimulating agents, and treatment of infections were the only therapies available. Subsequently, DNA methyltransferase inhibitors and immunomodulators showed survival benefits in MDS, leading to additional research on the efficacy of novel erythroid maturation agents in the setting of MDS-related anemia. Currently, multiple innovative therapies—including multikinase inhibitors, NEDD8-activating enzyme inhibitors, isocitrate dehydrogenase 1/2 inhibitors, BCL-2 inhibitors, and CD47 antibodies—are being investigated to improve care across different MDS populations, including low-, intermediate-, or high-risk patients, elderly individuals with comorbid conditions, and those ineligible for intensive treatment.

In this CME web broadcast, an expert panel will discuss the diagnosis and management of MDS. The panelists will review innovative treatment strategies, prognostic scoring systems for risk stratification, and how hematologist-oncologists can recommend appropriate therapeutic options for patients with MDS.